Harry Simeonidis takes control of GE Healthcare in the ANZ region.

It could be a long way off before we can take a 'caveolin pill' to fix our livers after a big night out, but a recent breakthrough by collaborating scientists in Brisbane and Barcelona has brought the possibility a little closer, as Fiona Wylie reports.

Sydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS).

Sydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management.

Since she took the top job at AusBiotech on the eve of the BIO conference earlier this year, Anna Lavelle has done a lot of listening. Now she's ready to talk -- about her role and her vision for the organisation.

Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.

Expat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham.

Cochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers.

Mutual fatigue, and the peculiar challenges involved in negotiating with New Zealand's research and health-service agencies, were behind the mediated settlement of the Auckland District Health Board's dispute with Melbourne biotech Genetic Technologies (ASX:GTG) over licensing fees for GTG's non-coding DNA gene testing and mapping technology in NZ.

University of Auckland scientists are using an array of computers, famous for their use to create Oscar-winning special effects in the Lord of the Rings trilogy, in HIV/AIDS research.